Archive for September 23, 2015

Epidemiology and Prevention of Vaccine-Preventable Diseases

The Pink Book: Course Textbook – 13th Edition (2015)

The 13th Edition Epidemiology and Prevention of Vaccine-Preventable Diseases, a.k.a. the “Pink Book,” provides physicians, nurses, nurse practitioners, physician assistants, pharmacists, and others with the most comprehensive information on routinely used vaccines and the diseases they prevent.

Six appendices contain a wealth of reference materials including: vaccine minimum ages and intervals, current and discontinued vaccines, vaccine contents, foreign vaccine terms, and more.

To view online or download to print specific sections, see links below….

Chapter 1: Principles of Vaccination

Chapter 2: General Recommendations on Immunization

Chapter 3: Immunization Strategies for Healthcare Practices and Providers

Chapter 4: Vaccine Safety

Chapter 5: Storage and Handling

Chapter 6: Vaccine Administration

Chapter 7: Diphtheria

Chapter 8: Haemophilus influenzae

Chapter 9: Hepatitis A

Chapter 10: Hepatitis B

Chapter 11: Human Papillomavirus

Chapter 12: Influenza

Chapter 13: Measles

Chapter 14: Meningococcal Disease

Chapter 15: Mumps

Chapter 16: Pertussis

Chapter 17: Pneumococcal Disease

Chapter 18: Poliomyelitis

Chapter 19: Rotavirus

Chapter 20: Rubella

Chapter 21: Tetanus

Chapter 22: Varicella





September 23, 2015 at 7:33 pm

Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

MMWR Morb Mortal Wkly Rep. Sept.4, 2015 V.64 N.3 P.944-947

Miwako Kobayashi, MD1,2; Nancy M Bennett, MD3,4; Ryan Gierke, MPH1; Olivia Almendares, MSPH1; Matthew R Moore, MD1; Cynthia G. Whitney, MD1; Tamara Pilishvili, MPH1

Two pneumococcal vaccines are currently licensed for use in the United States: the 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co., Inc.]).

The Advisory Committee on Immunization Practices (ACIP) currently recommends that a dose of PCV13 be followed by a dose of PPSV23 in all adults aged ≥65 years who have not previously received pneumococcal vaccine and in persons aged ≥2 years who are at high risk for pneumococcal disease because of underlying medical conditions (Table) (1–4).

The recommended intervals between PCV13 and PPSV23 given in series differ by age and risk group and the order in which the two vaccines are given (1–4).

On June 25, 2015, ACIP changed the recommended interval between PCV13 followed by PPSV23 (PCV13–PPSV23 sequence) from 6–12 months to ≥1 year for immunocompetent adults aged ≥65 years.

Recommended intervals for all other age and risk groups remain unchanged. This report outlines the rationale for this change and summarizes the evidence considered by ACIP to make this recommendation……..



September 23, 2015 at 7:23 pm

Methicillin-Susceptible, Vancomycin-Resistant Staphylococcus aureus, Brazil

Emerging Infectious Diseases October 2015 V.21 N.10

Diana Panesso, Paul J. Planet, Lorena Diaz, Jean-Emmanuel Hugonnet, Truc T. Tran, Apurva Narechania, Jose M. Munita, Sandra Rincon, Lina P. Carvajal, Jinnethe Reyes, Alejandra Londoño, Hannah Smith, Robert Sebra, Gintaras Deikus, George M. Weinstock, Barbara E. Murray, Flavia Rossi, Michel Arthur, and Cesar A. AriasComments to Author

Author affiliations: Universidad El Bosque, Bogota, Colombia (D. Panesso, P.J. Planet, L. Diaz, J.M. Munita, S. Rincon, L.P. Carvajal, J. Reyes, G. M. Weinstock, C.A. Arias); University of Texas Medical School, Houston, Texas, USA (D. Panesso, T.T. Tran, J.M. Munita, A. Londoño, B.E. Murray, C.A. Arias); American Museum of Natural History, New York (P.J. Planet, A. Narechania); Columbia University, New York, New York, USA (P.J. Planet, A. Londoño, H. Smith); Centre de Recherche des Cordeliers, Paris, France (J.E. Hugonnet, M. Arthur); Université Pierre et Marie Curie, Paris (J.E. Hugonnet, M. Arthur); Université Paris Descartes, Paris (J.E. Hugonnet, M. Arthur); Clinica Alemana de Santiago, Santiago, Chile (J.M. Munita); Universidad del Desarrollo, Santiago (J.M. Munita); Icahn School of Medicine at Mount Sinai, New York (R. Sebra, G. Deikus); The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA (G.M. Weinstock); Universidade da São Paulo, São Paulo, Brazil (F. Rossi)

We report characterization of a methicillin-susceptible, vancomycin-resistant bloodstream isolate of Staphylococcus aureus recovered from a patient in Brazil.

Emergence of vancomycin resistance in methicillin-susceptible S. aureus would indicate that this resistance trait might be poised to disseminate more rapidly among S. aureus and represents a major public health threat.


Technical Appendix CDC

September 23, 2015 at 3:46 pm


September 2015
« Aug   Oct »

Posts by Month

Posts by Category